Bayer Pharma Signs Agreement with Vitiva
Vitiva has made repeated investments in its manufacturing facility to meet Bayer Pharma’s strict standards and requirements for high quality products and on-time delivery.
05/07/06 Bayer Pharma, Slovenia and Slovenian based nutraceuticals company Vitiva have announced a new broad technology collaboration. This joint venture will enable better utilization of the companies’ capabilities and reinforce their ongoing cooperation. It is based on exclusive isolation of esters from marigold flower. Bayer Pharma has registered a patent for a natural OTC product worldwide based on marigold flower extracts.
"This agreement with a leading pharmaceutical company represents a significant step for Vitiva," says Ohad Cohen, CEO of Vitiva. “This collaboration will stimulate development of innovative products and will deliver new solutions for consumers who prefer to use natural ingredients – an area in which Vitiva has earned an excellent reputation. We look forward to the opportunity to work together and are confident that this agreement will lay the foundation for ongoing cooperation between Bayer Pharma and Vitiva.”
Vitiva has made repeated investments in its manufacturing facility to meet Bayer Pharma’s strict standards and requirements for high quality products and on-time delivery. “Vitiva was chosen by Bayer Pharma for its advanced technologies and facilities and its expertise in the isolation of high-value natural extracts,” says Mr. Matjaz Mohar, supply chain manager at Bayer Pharma. “This agreement acknowledges that cutting-edge natural products and intellectual property protection are the foundation for the growth and success of our industry. Vitiva, a leading global supplier of natural rosemary antioxidants, has a strong commitment to serving its customers through innovation and high quality products.”
